Cardiothoracic Surgery |

Integration of Mesenchymal Stromal Cells Delivered in a Fibrin Sealant During the Initial Phases of Lung Parenchyma Healing in an Animal Model FREE TO VIEW

M. Teresa Gómez-Hernández, MD; Maria Rodríguez, MD; Marcelo Fernando Jiménez López, PhD; Dolores Ludeña, PhD; Begoña García-Cenador, PhD; Consuelo Cañizo, PhD
Author and Funding Information

Salamanca University Hospital, Salamanca, Spain

Chest. 2014;145(3_MeetingAbstracts):53A. doi:10.1378/chest.1824433
Text Size: A A A
Published online


SESSION TITLE: Thoracic Surgery Posters

SESSION TYPE: Poster Presentations

PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM

PURPOSE: In this study, we have assessed the ability of mesenchymal stromal cells MSCs to differentiate and to contribute in lung repair and how these cells are able to integrate in the initial healing process after a lung parenchyma injury in an animal model.

METHODS: MSCs were obtained from a human bone marrow aspirate and were grown in vitro. They were applied directly to lung parenchyma injuries induced in sterile conditions in eleven white rats using a fibrin polymer system (Tisseel®). Lung specimens were analyzed after 2, 4, 7 and 14 days of the application of the MSCs according to the different healing phases. The analysis consisted of hematoxylin-eosin staining and immunohistochemical study using antibodies binding specifically to human mitochondria.

RESULTS: MSCs identified by anti-human mitochondrial antibodies were found in all phases of the lung parenchyma scarring. After two days, these cells showed morphological characteristics of macrophages. Four days after, some of these cells had turned into fibroblasts. During the differentiation phase, coinciding with the seventh day, MSCs-derived fibroblasts were predominant. Fourteen days after the injury, only a small number of cells binding human mitochondrial antibodies were detected and they were well integrated in the repaired areas.

CONCLUSIONS: These findings indicate that human bone marrow-derived MSCs have the ability to integrate in the damaged parenchyma expressing different morphological features along the main healing phases and they can be effectively delivered using a fibrin sealant system.

CLINICAL IMPLICATIONS: Recent studies have suggested that mesenchymal stromal cells (MSCs) are promising candidates for cell-based tissue engineering, to repair or replace damaged tissues.

DISCLOSURE: The following authors have nothing to disclose: M. Teresa Gómez-Hernández, Maria Rodríguez, Marcelo Fernando Jiménez López, Dolores Ludeña, Begoña García-Cenador, Consuelo Cañizo

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543